Toulouse, October 21st, 2015 - VEXIM (FR0011072602 - ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announced that his CEO, Vincent Gardès, will attend and present at the following investor conferences in November and December:
Thursday November 5th in Paris at the Société Générale Corporate & Investment Banking conference « Healthcare - biotech & medtech CEO conference ".
Wednesday and Thursday December 9th and 10th in Geneva at the 7th « Geneva European Midcap Event 2015 » edition.
Next Communication:
FY 2015 Sales results: January 15th 2016*
*indicative dates
About Vexim, the innovative back microsurgery specialist Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital[1] and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland, the United Kingdom and United States, as well as distributors in Turkey, Argentina, Taiwan, Belgium, Estonia, Poland, Portugal, South Africa, Saudi Arabia, Colombia, Panama, Venezuela, Chile, Peru and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil. Vexim has been listed on NYSE Alternext Paris since May 2012.
For further information, please visit www.vexim.com
SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.
Contacts
VEXIM
Vincent Gardès
CEO
investisseur@vexim.com
Tel: +33 5 61 48 48 38
Alize RP
Relations presse
Caroline Carmagnol
vexim@alizerp.com
Tél : 01 44 54 36 66 / 06 64 18 99 59
LifeSci Advisors LLC
Investor Relations
Michael Wood
www.lifesciadvisors.com
+1 646 597 6983
Help employers find you! Check out all the jobs and post your resume.
Thursday November 5th in Paris at the Société Générale Corporate & Investment Banking conference « Healthcare - biotech & medtech CEO conference ".
Wednesday and Thursday December 9th and 10th in Geneva at the 7th « Geneva European Midcap Event 2015 » edition.
Next Communication:
FY 2015 Sales results: January 15th 2016*
*indicative dates
About Vexim, the innovative back microsurgery specialist Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital[1] and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 60 members on its staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland, the United Kingdom and United States, as well as distributors in Turkey, Argentina, Taiwan, Belgium, Estonia, Poland, Portugal, South Africa, Saudi Arabia, Colombia, Panama, Venezuela, Chile, Peru and Ecuador and in the following countries where the product is currently being registered: Mexico, Brazil. Vexim has been listed on NYSE Alternext Paris since May 2012.
For further information, please visit www.vexim.com
SpineJack®, a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.
SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.
Contacts
VEXIM
Vincent Gardès
CEO
investisseur@vexim.com
Tel: +33 5 61 48 48 38
Alize RP
Relations presse
Caroline Carmagnol
vexim@alizerp.com
Tél : 01 44 54 36 66 / 06 64 18 99 59
LifeSci Advisors LLC
Investor Relations
Michael Wood
www.lifesciadvisors.com
+1 646 597 6983
Help employers find you! Check out all the jobs and post your resume.
